Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QuEST study: Juzentaihoto with neoadjuvant chemotherapy for esophagogastric cancer
jRCTs071200105Active, not recruiting
- Sponsor
- Tsumura & Co.
- Start
- Apr 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of juzentaihoto in esophageal cancer and gastric cancer (GC) (2 arms), sponsored by Tsumura & Co. Primary endpoint: Comprehensive quality of life. Started Apr 2021; status: active, not recruiting.
02
Drugs
juzentaihoto
03
Conditions
esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on jRCTs071200105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071200105.